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A B S T R A C T
Ischemic stroke is amongst the leading causes of death and disabilities. The available treatments are suitable for
only a fraction of patients and thus novel therapies are urgently needed. Blockage of one of the cerebral arteries
leads to massive and persisting inﬂammatory reaction contributing to the nearby neuronal damage. Targeting
the detrimental pathways of neuroinﬂammation has been suggested to be beneﬁcial in conditions of ischemic
stroke. Nuclear receptor 4A-family (NR4A) member Nurr1 has been shown to be a potent modulator of harmful
inﬂammatory reactions, yet the role of Nurr1 in cerebral stroke remains unknown. Here we show for the ﬁrst
time that an agonist for the dimeric transcription factor Nurr1/retinoid X receptor (RXR), HX600, reduces mi-
croglia expressed proinﬂammatory mediators and prevents inﬂammation induced neuronal death in in vitro co-
culture model of neurons and microglia. Importantly, HX600 was protective in a mouse model of permanent
middle cerebral artery occlusion and alleviated the stroke induced motor deﬁcits. Along with the anti-in-
ﬂammatory capacity of HX600 in vitro, treatment of ischemic mice with HX600 reduced ischemia induced Iba-1,
p38 and TREM2 immunoreactivities, protected endogenous microglia from ischemia induced death and pre-
vented leukocyte inﬁltration. These anti-inﬂammatory functions were associated with reduced levels of brain
lysophosphatidylcholines (lysoPCs) and acylcarnitines, metabolites related to proinﬂammatory events. These
data demonstrate that HX600 driven Nurr1 activation is beneﬁcial in ischemic stroke and propose that targeting
Nurr1 is a novel candidate for conditions involving neuroinﬂammatory component.
1. Introduction
Ischemic stroke is a severe cerebrovascular disease caused by
blockage of blood ﬂow into the brain. It is one of the leading causes of
death (GBD, 2015) inﬂuencing mainly the elderly, yet a growing por-
tion of individuals aﬀected are still at working age (Kissela et al., 2012;
Béjot et al., 2014). If not causing imminent death, stroke is likely to lead
to permanent disabilities markedly diminishing the quality of life of the
aﬀected individuals and their families. Thus, stroke is causing an en-
ormous burden for the society and economy (Stroke Facts, 2017). While
mechanical thrombectomy is highly beneﬁcial in large vessel occlusions
in the anterior circulation (Evans et al., 2017), recombinant tissue
plasminogen activator (r-tPA) still remains the only clinically approved
pharmacological treatment for cerebral stroke, yet it is suitable for only
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a fraction of patients due to its very narrow therapeutic time window
and severe side eﬀects (Quain et al., 2008). Thus, there is a pressing
need for new stroke therapies.
Blockage of blood ﬂow into the brain parenchyma initiates a com-
plex cascade of events leading to subsequent inﬂammatory reaction.
This is evident by the activation of resident immune cells, especially
microglia, accumulation of various inﬂammatory mediators in the is-
chemic tissue and inﬁltration of peripheral immune cells into the af-
fected area (Jin et al., 2010). Microglia play important roles in the
normal brain physiology, enhance neurogenesis, produce neurotrophic
factors (Raivich et al., 1999) and clear the dying debris after ischemic
insult, yet their activation also promotes nearby neuronal death by
secretion of pro-inﬂammatory cytokines such as tumor necrosis factor
(TNF), interleukins and nitric oxide (Banati et al., 1993).
Nuclear receptors are ligand-activated transcription factors and key
regulators of a wide range of homeostatic processes from development
to diﬀerent areas of metabolism (Chawla et al., 2001). They can be
divided into two categories, where type 1 nuclear receptors include
well-known steroid receptors such as glucocorticoid and estrogen re-
ceptors. Function of type 2 nuclear receptors is based on their ability to
form heterodimers with the retinoid X receptor (RXR), and this RXR
heterodimer activation is known to have neuroprotective eﬀects in
neurodegenerative diseases such as Alzheimer’s disease (AD) and Par-
kinson’s disease (PD) (Skerrett et al., 2014). The nuclear receptor 4A
-family (NR4A) diﬀers from the other type 2 nuclear receptors in a way
that they lack the ligand binding pocket, thus functioning as ligand-
independent transcription factors. A member of this receptor family
(along with NR4A1 or Nurr77 and NR4A3 or Nor-1) is NR4A2, also
referred to as nuclear receptor related 1 protein or Nurr1. These re-
ceptors are constitutively active but can also signal in complex with
RXRs. Thus, the transcriptional activity of these receptors can be in-
duced by agonists which recognize the RXR-NR4A heterodimer com-
plex. 4-[5H-2,3-(2,5-Dimethyl-2,5-hexano)-5-methyldibenzo[b,e][1,4]
diazepin-11-yl]benzoic acid, HX600, is a synthetic agonist for the RXR-
NR4A heterodimer complex (Umemiya et al., 1997; Morita et al., 2005).
These receptors are abundantly expressed in the brain in diﬀerent
neuronal cell types (Xiao et al., 1996; Yasuyoshi et al., 2003;
Kadkhodaei et al., 2013), microglia and astrocytes (Saijo et al., 2009),
and as well in peripheral immune cells (Sekiya et al., 2013) and other
tissues in the periphery (Pearen and Muscat, 2010).
Nurr1 activation has been shown to confer neuroprotection
(Barneda-Zahonero et al., 2012; Hammond and Safe, 2015; Volakakis
et al., 2010; Hammond et al., 2018) and is anti-inﬂammatory through
its ability to suppress nuclear factor kappaB (NFκB) activation (Saijo
et al., 2009; De Miranda et al., 2015), yet there are no reports on
whether Nurr1 induction is neuroprotective in models of ischemic
stroke. Ischemia induced Nurr1 mRNA upregulation has been reported
in global ischemia in gerbils (Honkaniemi and Sharp, 1996) and in rats
with permanent middle cerebral artery occlusion (Honkaniemi et al.,
1997), whereas protein levels of Nurr1 were shown to be decreased in
mice subjected to transient ischemia (Erdö et al., 2004).
Our hypothesis was that HX600 facilitates neuronal survival by in-
hibiting inﬂammation via activation of Nurr1. We tested this hypothesis
in an in vitro – model of inﬂammation induced neuronal death and in
mouse model of permanent middle cerebral artery occlusion using
several analytical methods.
2. Materials and methods
2.1. Primary microglial culture
Primary microglial cultures were prepared from C57BL/6J mice
(Jackson laboratories) of postnatal day 0–3 as described previously
(Malm et al., 2015). Brieﬂy, brains of decapitated mice were dissected
and tissue was incubated in DMEM-F12 supplemented with 1% peni-
cillin-streptomycin and Trypsin-EDTA after mechanical dissociation (all
ThermoFisher Scientiﬁc, Waltham, MA, USA). The trypsin was in-
activated with complete media (DMEM-F12, 10% fetal bovine serum,
1% penicillin-streptomycin, all ThermoFisher Scientiﬁc, Waltham, MA,
USA), the tissue homogenized, plated on 15 cm dishes and grown at
+37 °C 5% CO2 for three weeks. The astrocyte layer from the mixed
glial culture was trypzinized and the remaining microglia removed,
counted and plated on 48-well-plates at the density of 125 000 cells/
well. Microglia were pre-treated with 1 µM HX600 for 24 h, after which
the cells were exposed to 50 ng/ml lipopolysaccharide (LPS L2630,
serotype O111:B4, Sigma Aldrich, St. Louis, MO, USA) for 3 h, while
keeping the concentration of HX600 (synthetized by H. Kagechika)
unaltered.
2.2. Primary cortical neuron culture
Primary cortical neuron cultures were prepared from mouse em-
bryos of embryonic day 15 as described by Malm et al. (2015). Brieﬂy,
the cortices were dissected and tissue dissociated with 0.0125% trypsin
(for 15min at 37 °C, Sigma-Aldrich, St. Louis, MO, USA). After trypsin
inactivation and washing the cells were counted and plated on 48-well-
plates (coated with poly-D-lysine, Sigma-Aldrich, St. Louis, MO, USA) at
a density of 125 000 cells/well in Neurobasal media supplemented with
2% B27 and 500 µM L-glutamine (all ThermoFisher Scientiﬁc, Wal-
tham, MA, USA) and 10 µg/ml of gentamicin (Sigma Aldrich, St. Louis,
MO, USA). On day 5 in vitro (DIV) 50% of media was changed, and on
day 6 in vitro neurons were treated with 100 nM or 1 µM HX600 in the
presence of 500 µM glutamate for 24 h. Alternatively, on DIV 6 the
neurons were pre-exposed to HX600 for 24 h and followed by treatment
with glutamate (500 µM) for another 24 h, without changing the HX600
concentration (100 nM or 1 µM). Neuronal viability was assessed using
MTT assay.
2.3. Neuron-BV2 co-culture and viability assay
For neuron-BV2 co-culture experiment primary cortical neuron
culture was ﬁrst prepared as described above. On DIV 5 negative con-
trol siRNA (ThermoFisher Scientiﬁc, Waltham, MA, USA) or Nurr1
siRNA (Silencer® select siRNA for Nr4a2, ThermoFisher Scientiﬁc,
Waltham, MA, USA) transfected BV2 cells were seeded on top of neu-
rons at density of 1:5 (25 000 BV2 cells per 125 000 neurons) and left
for 2 h to allow attachment. The cells were pretreated with 1 µM HX600
for 6 h, after which they were exposed to 100 ng/ml LPS (L2630, ser-
otype O111:B4, Sigma Aldrich, St. Louis, MO, USA) and 30 ng/ml in-
terferon gamma (IFNγ, Sigma-Aldrich, St. Louis, MO, USA) for 48 h.
Concentration of HX600 was kept constant (1 µM) during the LPS/IFNγ
exposure. After the exposure the cells were rinsed with PBS and ﬁxed
with 4% PFA for 20min. The cells were washed again in PBS (pH 7.4)
and neuronal viability in co-culture was assessed as described pre-
viously (Gresa-Arribas et al., 2012). Brieﬂy, the co-cultures were
stained with MAP-2 peroxidase labelling and the ABTS peroxidase
substrate kit (Vector) was used to develop the color according to
manufacturer’s instruction. Green colored product was formed after
incubation for 30min with ABTS kit in the dark. The plate was gently
shaked and 150 µL of the substrate solution was then transferred to the
96 well plate and the absorbance was measured with microtiter plate
reader Victor 2.0 (Perkin Elmer, MA, USA) at 405 nm. Results were
calculated as relative absorbances compared to control wells. Alter-
natively, the co-cultures were stained with MAP-2 antibody (Sigma-
Aldrich, St. Louis, MO, USA) followed by incubation with Alexa-488
conjugated secondary antibody. The extent of MAP-2 immunoreactivity
as indicative of neuronal viability was imaged under ﬂuorescent mi-
croscope and quantiﬁed using ImagePro software (Media Cybernetics
Inc., Rockville, MD, USA).
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2.4. Animals
For the permanent ischemia studies, adult (3–7months old) male
Balb/cOlaHsd mice (Harlan Laboratories B.V., An Venrey, Netherlands)
were used. Total of 108 mice were used in the study. Mice were in-
dividually housed in controlled humidity, temperature and light con-
ditions, and they had ad libitum access to food and water.
Randomization to treatment groups was carried out by using GraphPad
QuickCalcs (GraphPad Software, San Diego, CA, USA), and mice of
diﬀerent ages were distributed randomly to all groups. All data analyzes
were performed blinded to the experimental groups. All the animal
experiments followed the Council of Europe Legislation and Regulation
for Animal Protection and were approved by the National Animal
Experiment Board of Finland. Every eﬀort was made to minimize the
harm and suﬀering of the animals.
2.5. Ischemia surgeries and treatment of mice with HX600
For permanent occlusion of the middle cerebral artery (pMCAo), the
anesthesia was induced using 5% isoﬂurane in 30% O2 and 70% N2O
and maintained at 2% isoﬂurane during the surgery. The left MCA was
permanently occluded as previously described (Dhungana et al., 2013).
Brieﬂy, a hole (1 mm in diameter) was drilled on the temporal bone to
expose the MCA. The dura was removed, after which the artery was
lifted and occluded using a thermocoagulator (Aaron Medical Industries
Inc., Clearwater, FL, USA). MCA occlusion was conﬁrmed by cutting the
artery after which the temporal muscle was replaced and the wound
was sutured. The body temperature of the animals was maintained at
37 ± 0.5 °C during the whole procedure by using a heating pad. The
respiratory rate and temperature were monitored throughout the sur-
gery. The sham operated mice underwent the same procedures except
the occlusion of the MCA. Mice with hemorrhages visible in magnetic
resonance imaging (MRI), bleeding during the surgery and unsuccessful
induction of ischemia were excluded from further analysis. Altogether 8
mice were excluded from the study.
The mice were treated with HX600 dissolved in standard suspension
vehicle (SSV) solution (containing 0.9% (w/v) NaCl, 0.5% (w/v) so-
dium carboxymethylcellulose, 0.5% (v/v) benzyl alcohol and 0.4% (v/
v) Tween®80, all Sigma-Aldrich, St. Louis, MO, USA), or SSV alone by
oral gavage. The dose of 60mg/kg was administered immediately after
pMCAo surgery and every 24 h thereafter. Mice were sacriﬁced at 1 or
3 days post injury (dpi) and the tissues were collected as described
below.
2.6. Post-surgery evaluation of locomotor activity
Latency-to-move is a simple test which has been shown to be able to
reveal motor deﬁcits induced by pMCAo (Lubjuhn et al., 2009). We
utilized this test to assess motor function of the mice at 1 day after the
ischemic insult. The mice (7–12 in each treatment group) were placed
on a ﬂat surface and the time to move one body length (7 cm) was
recorded. Two trials were allowed for each mouse. The person per-
forming the test was blinded to the treatment groups.
2.7. Measurement of lesion volume
The lesion volumes were determined by magnetic resonance ima-
ging (MRI) at 48 h after pMCAO. A vertical 9.4 T Oxford NMR 400
magnet (Oxford Instrument PLC, Abington, UK) was used for visualizing
the lesion as described previously (Dhungana et al., 2013). The mice
were anaesthetized with 5% isoﬂurane in 30% O2 and 70% N2O, and
multislice T2-weighted images (repetition time 3000ms, echo time
40ms, matrix size 128 x 256, ﬁeld of view 19.2 x 19.2mm2, slice
thickness 0.8mm and number of slices 12) were obtained. The images
were analyzed by utilizing in-house made software Aedes in the Matlab
environment (Math-works, Natick, MA, USA). The infarction volume
was calculated by using the following formula: Infarct volume = (volume
of left hemisphere − (volume of right hemisphere − measured infarct vo-
lume))/volume of left hemisphere (Shuaib et al., 2002).
2.8. Immunohistochemistry
Mice were euthanized at 1 or 3 dpi (5–8 mice per group) for tissue
collection. Mice were anesthetized with 250mg/kg Avertin® (Sigma-
Aldrich, St. Louis, MO, USA) and perfused transcardially with saline
containing 2500 IU/L heparin (Heparin LEO 5000 IU/ml, Leo Pharma
A/S, Ballerup, Denmark). The brains were removed and post-ﬁxed in
4% paraformaldehyde (PFA, Sigma-Aldrich, St. Louis, MO, USA) for
20 h, followed by cryoprotection in 30% sucrose for 48 h. The brains
were frozen on liquid nitrogen and cut into 20 µm thick sections with a
cryostat (Leica Microsystems, Wetzlar, Germany). All im-
munohistochemical stainings were carried out on six consecutive sec-
tions at 400 µm intervals.
The brain sections were incubated overnight at room temperature
with primary antibodies (Leucocyte common antigen [CD45] 1:100
dilution, Bio-Rad, Hercules, CA, USA; Cluster of diﬀerentiation 68
[CD68] 1:2000 dilution, Bio-Rad, Hercules, CA, USA; Glial ﬁbrillary
acidic protein [GFAP] 1:500 dilution, ABR Aﬃnity BioReagents,
Golden, CO, USA; Ionized calcium-binding adapter molecule 1 [Iba-1]
1:250 dilution, Wako Chemicals, Tokyo, Japan; Lymphocyte antigen 6
complex locus G6D [Ly6-G neutrophil] 1:100 dilution, BioLegend, San
Diego, CA, USA; Phosphorylated P38 mitogen-activated protein kinase
[phospho-p38] 1:100 dilution, Cell Signaling Technology Inc., Danvers,
MA, USA; Triggering receptor expressed on myeloid cells 2 [TREM2]
1:100 dilution, Lifespan Biosciences, Seattle, WA, USA). All stainings
except the Ly6-G neutrophil stain required antigen retrieval in 10mM
aqueous solution of sodium citrate dihydrate (pH 6, preheated to
+92 °C, Sigma-Aldrich, St. Louis, MO, USA) before application of pri-
mary antibodies. Secondary antibodies were applied on sections after
three washes in 0.05% Tween®20 (Sigma-Aldrich, St. Louis, MO, USA)
in PBS. Fluorescent Alexa 488 or 568-conjugated secondary antibodies
(1:200 dilution, Abcam, Cambridge, UK) were used for visualization of
the immunoreactivities. For phospho-p38 and TREM2 stainings bioti-
nylated secondary antibody (1:200 dilution, Vector Laboratories,
Burlingame, CA, USA) was used, followed by reaction with avidin-
biotin complex reagent (1:200 dilution, Vector Laboratories,
Burlingame, CA, USA) according to the instructions provided by the
manufacturer. The bound phospho-p38 immunoreactivity was then
visualized by development with nickel-enhanced 3,3′-diaminobenzi-
dine, and TREM2 was visualized following the instructions of Tyramide
Signal Ampliﬁcation -kit (Perkin Elmer, MA, USA).
For quantiﬁcation of the immunoreactivities in the peri-ischemic
area, a 718×532 μm cortical area adjacent to the infarct border was
imaged using 10× magniﬁcation on an AX70 microscope (Olympus
corporation, Tokyo, Japan) with an adjacent digital camera (Color View
12 or F-View, Soft imaging system, Muenster, Germany) running
AnalySis software (Soft Imaging System). For CD45 and neutrophil
stainings, images of equal size were taken from the lesion area, where
the majority of the immunoreactivity was observed. Quantiﬁcation of
the immunoreactivities was performed using ImagePro Plus software
(Media Cybernetics Inc., Rockville, MD, USA) at a predeﬁned range and
presented as relative immunoreactive area. All analyses were per-
formed blinded to the study groups.
2.9. Brain cell isolation and ﬂow cytometry
4–6 mice from each treatment group were perfused transcardially at
3 dpi with heparinized saline as above. Brains (cerebellum removed)
were isolated and placed on ice in Hanks balanced salt solution
(ThermoFisher Scientiﬁc, Waltham, MA, USA). The tissue was minced
on ice in digest buﬀer with 0.5 mg/ml collagenase type IV
(Worthington, Lakewood, NJ, USA), 25 u/ml DNAse I and RPMI-1640
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(both from Sigma-Aldrich), and after that incubated for 20min at
+37 °C, 5% CO2. The tissue was put back on ice, triturated and passed
through 70 µm and 40 µm cell strainers (Falcon, Corning, NY, USA).
Homogenates were centrifuged at 450g for 5min, resuspended in
Miltenyi Myelin Debris Removal Beads II (Miltenyi, Cologne, Germany)
and incubated at +4 °C for 15min. After incubation the samples were
washed with cold MACS buﬀer (PBS including 0.5% Bovine Serum
Albumin, both from Sigma-Aldrich) and centrifuged at 400g for 10min,
after which the pellets were resuspended into cold MACS buﬀer.
Samples were applied to magnetic LD columns (Miltenyi) using 50 µm
CellTrics pre-ﬁlters (Sysmex, Norderstedt, Germany), and the ﬂow-
through was collected on ice, counted and spun at 400g for 10min, and
ﬁnally resuspended in RPMI-1640.
Cell surface staining was done using 200,000–300,000 cells per
mouse in round-bottom polypropylene 96-well-plates (Corning). Cells
were washed with PBS, stained with Zombie NIR ﬁxable viability dye
(BioLegend, San Diego, CA, USA) for 15min at RT, then blocked with
CD16/32 (clone 24G2, BD Biosciences, San Jose, CA, USA) and stained
with the following antibodies: CD45 PerCP-Cy5.5 (clone 30 F11,
eBioscience, San Diego, CA, USA), CD11b PECy7 (clone M1/70,
eBioscience), Ly6G FITC (clone 1A8, BioLegend) F4/80 PE (clone A3-1,
AbD Serotec, Oxford, UK), and Ly6C APC (clone AL-21, BD Biosciences)
for 30min at +4 °C. Cells were washed twice with PBS and ﬁxed with
0.5% Ultra Pure formaldehyde (ThermoFisher Scientiﬁc, Waltham, MA,
USA). Samples were acquired on BD FACSAria III equipped with 488-
and 633-nm lasers with standard conﬁguration. Data were analyzed
with FCSExpress v5 (DeNovo Software Glendale, CA, USA).
2.10. Quantitative real-time PCR
The relative expression levels of inducible nitric oxide synthase
iNOS (NOS2), macrophage receptor with collagenous structure
(Marco), interleukin 1 beta IL-1β (Il1b), interleukin 6 IL-6 (Il6), matrix
metallopeptidase 9 (Mmp9) and complement component 3 (C3) were
measured from primary microglia exposed to LPS and HX600 using
quantitative PCR (qPCR). Total RNAs were isolated using RNeasy mini
kit (Qiagen, CA, USA) according to the manufacturer’s instructions. The
concentration and purity of RNA samples were determined using a
NanoDrop 2000 (Thermo Fisher Scientiﬁc). Complementary DNA
(cDNA) was synthesized by using 500 ng of total RNA, Maxima reverse
transcriptase, dNTP and random hexamer primers (Life technologies,
CA, USA). The ﬁnal concentration of cDNA was 2.5 ng/µl. qPCR was
run using the StepOne Plus Real Time PCR system (Applied Bioscience,
CA, USA). Gene expression analysis was carried out using comparative
Ct method (△△CT) where the threshold cycle of the target genes was
normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH,
ThermoFisher Scientiﬁc, Waltham, MA, USA) and ribosomal RNA (S18
endogenous calibrator, ThermoFisher Scientiﬁc, Waltham, MA, USA)
internal housekeeping gene controls (△CT). The mRNA expression is
presented as a fold change.
2.11. Microglia morphology measurement
The morphological analysis of Iba-1 expressing cells was done as
previously described (Huuskonen et al., 2017) at one day after
ischemia. Area and perimeter of the cells, along with other parameters,
were analyzed using Matlab v2013b. Zeiss LSM 700 confocal micro-
scope (Zeiss Inc., Maple Grove, USA) combined with digital camera
(Color View 12 or F-View; Soft Imaging System, Münster, Germany)
running Zen 2012 Image Analysis Software (Zeiss Inc., Maple Grove,
USA) was utilized in capturing the images for the analysis.
2.12. Metabolic proﬁling
Tissue samples from the peri-ischemic area and from the con-
tralateral side, collected at 1 dpi as described above, were weighed and
80% methanol was added (v/v H2O, LC-MS Ultra CHROMASOLV®,
Fluka) in a ratio of 350 µL solvent/100mg tissue. Extraction was fa-
cilitated by breaking the tissue with Teﬂon coated plastic staﬀ followed
with water sonication for 10min (BRAUSON GWB 2200). Samples were
then vortexed and centrifuged (Eppendorf centrifuge 5804 R,
13000 rpm, 5min at 4 °C). Supernatant was then collected and ﬁltered
to HPLC bottles through Acrodisc CR 4mm (0.45 µm) ﬁlter. Quality
control samples were made by taking 5 µL of solution from each sample.
The samples were analyzed using a UHPLC-qTOF-MS system
(Agilent Technologies, Waldbronn, Karlsruhe, Germany) that consisted
of a 1290 LC system, a Jetstream electrospray ionization (ESI) source,
and a 6540 UHD accurate-mass qTOF spectrometry as described in
Puurunen et al. (2016). Two diﬀerent chromatographic techniques
were used, i.e. reversed phase (RP) and hydrophilic interaction (hilic)
chromatography and acquired data in both positive (+) and negative
(−) polarity. The sample tray was kept at 4 °C during the analysis.
MassHunter Acquisition B.04.00 (Agilent Technologies) software was
used for data acquisition. The quality control samples were injected in
the beginning of the analysis as well as every 12th injection. The ana-
lysis order of the samples was randomized.
The mass spectrometry data processing was performed using
MassHunter Proﬁnder B.06.00 (Agilent Technologies, USA). The batch
recursive feature extraction function was used to extract ion to mole-
cular features exhibiting isotopic peaks, dimers, and common adducts.
Final alignment and quality control of peak spectra were done manu-
ally. The data were transferred as compound exchange format ﬁles into
the Mass Proﬁler Professional (MPP) software (version 13, Agilent
Technologies) for statistical analysis. MS-DIAL ver. 2.52 (Tsugawa
et al., 2015) and MassHunter Qualitative Analysis B.07.00 (Agilent
Technologies, USA) softwares were used for metabolite identiﬁcation
against MSMS spectra found in public and in-house standard libraries
(respectively).
2.13. Statistics
Statistical analyzes were performed using GraphPad Prism software
5.03 (GraphPad Software, LaJolla, CA, USA), with either unpaired two-
tailed t-test, one-way ANOVA or two-way ANOVA as appropriate.
Cohen’s d eﬀects sizes (mean(cases)− mean(controls)/((SD(cases) + SD
(controls))/2) were calculated for the metabolomics data. The statistical
test used and n-numbers are indicated in each ﬁgure legend. p-values
less than 0.05 were considered to be statistically signiﬁcant.
Statistically signiﬁcant outliers as calculated using GraphPad Prism
QuickCalcs were excluded from the datasets. All data are presented as
mean ± standard deviation (SD), unless mentioned otherwise.
3. Results
3.1. HX600 is not directly neuroprotective against glutamate exposure in
vitro
Since Nurr1 activation has been shown to confer neuroprotection in
models of PD and in vitro in neuropathological conditions (Volakakis
et al., 2010), we analyzed whether HX600 is neuroprotective in primary
cortical neurons exposed to glutamate mimicking ischemia-related ex-
citotoxicity in vitro. Primary cortical neurons were exposed to 100 nM
and 1 μM concentrations of HX600 in the presence of glutamate for
24 h, with or without 24 h pretreatment with HX600. Neuronal viability
measurement using MTT revealed that HX600 is unable to prevent the
direct, glutamate induced neuronal death Fig. 1).
3.2. HX600 inhibits the expression of inﬂammatory mediators in primary
microglia and prevents inﬂammation induced neuronal death
Due to the known ability of Nurr1 to exhibit anti-inﬂammatory
functions, we evaluated whether HX600 alleviates microglial
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proinﬂammatory activation. Primary microglia were pretreated with
HX600 for 24 h followed by exposure to LPS for 3 h, after which the
mRNA levels of inﬂammatory mediators were measured by qPCR.
HX600 signiﬁcantly reduced the expression of NOS2 (iNOS), Marco,
Il1b (IL-1β), Il6 (IL-6) and Mmp9 in LPS treated primary microglia
Fig. 2A–E) but failed to alter the expression level of C3 Fig. 2F). To
evaluate whether the anti-inﬂammatory eﬀect of HX600 is able to
confer neuroprotection, we used a co-culture model in which primary
microglia or BV2 cells are plated on top of primary neurons and ex-
posed to LPS and INF-γ resulting in inﬂammation induced neuron
death. Pretreatment of the neuron – primary microglia co-cultures with
HX600 signiﬁcantly prevented the inﬂammation induced neuronal
death as assessed by MAP-2 immunoreactivity Fig. 3A, B). To conﬁrm
that the eﬀect of HX600 is mediated through induction in Nurr1, BV2
cells were transfected with Nr4a2 siRNA. This resulted in 40% knock-
down in the expression level of Nurr1 Fig. 3C). Transfection of BV2 cells
with Nr4a2 siRNA prevented the HX600 induced protection against
inﬂammation induced neuronal death Fig. 3D), whereas mock trans-
fection of BV2 cells with control siRNA failed to prevent the HX600
eﬀect Fig. 3E).
3.3. HX600 reduces ischemic damage and alleviates motor deﬁcits in
permanent ischemia model
To evaluate whether HX600 provides neuroprotection in vivo,
HX600 was administered to ischemic mice immediately after ischemia
surgery and thereafter every 24 h. Quantiﬁcation of the lesion volumes
at 48 h post stroke revealed that mice treated with HX600 had lesion
size 21% smaller than vehicle treated mice Fig. 4A). Fig. 4 B and 4C
depict typical examples of the MRI-images of mice treated with vehicle
or HX600, respectively. Mice subjected to pMCAo exhibited sig-
niﬁcantly impaired locomotor activity as measured by Latency-to-move
test at 1 dpi; stroke caused the latency time to double when compared
to sham-operated mice. These deﬁcits were no longer evident in ani-
mals treated with HX600 Fig. 4D).
3.4. HX600 reduces Iba-1, phospho-p38 and TREM-2 immunoreactivities in
the ischemic brain
In order to evaluate the impact of HX600 treatment on in-
ﬂammatory activation in the ischemic brain, series of im-
munohistochemical stainings were carried out to assess which cell types
of the brain are aﬀected by the treatment. HX600 had no eﬀect on CD45
(a marker for microglia/macrophages), GFAP (a marker of astrocytic
activation), CD68 (a marker for cells with phagocytic activity) or Ly6G
neutrophil immunoreactivities (data not shown), but instead, it mark-
edly reduced the extent of Iba-1 (a marker for activated microglia),
phospho-p38 (activated by e.g. inﬂammatory cytokines) and TREM2 (a
marker of phagocytosis) immunoreactivities in the aﬀected area at day
1 post ischemia Fig. 5). To further evaluate the impact of HX600 on
microglial activation, we carried out quantitative analysis of microglial
morphology which showed that HX600 increased the Iba-1 positive cell
perimeter and decreased the Area/Perimeter -ratio Fig. 6).
3.5. HX600 treatment normalizes proportions of CD45Hi CD11bLow and
Ly6CHi CD45Low cells in the ischemic brain
In order to more speciﬁcally evaluate the immune cells of the is-
chemic brain aﬀected by HX600 treatment, we analyzed proportions of
diﬀerent immune cell types using ﬂow cytometry on freshly isolated
cells from the ischemic animals at 3 days post stroke, the time of the
peak in leukocyte inﬁltration. As expected, ischemia induced a
Fig. 1. HX600 is not directly neuroprotective against glutamate induced neu-
ronal death. Primary cortical neurons were exposed to 100 nM or 1 µM ﬁnal
concentration of HX600 together with 500 µM glutamate (Glut) for 24 h (A).
Alternatively the cells were pretreated with HX600 for 24 h, and thereafter
exposed to glutamate for another 24 h while concentration of HX600 was kept
unaltered (B). Neuronal viability was measured using MTT assay. HX600 alone
did not aﬀect neuronal viability, but neither of the concentrations of HX600
was able to prevent the glutamate induced neuronal death. n=5 wells in each
group. The assay was repeated four times with similar results. 1-way ANOVA
with Bonferroni post test, ***p < 0.0001.
Fig. 2. HX600 reduces expression of inﬂammatory
mediators in microglia. Primary microglia were pre-
exposed to HX600 for 24 h after which the cells were
stimulated with LPS for 3 h. Stimulation of NR4A
pathway by HX600 reduced the expression of mRNA
levels of NOS2 (iNOS, A) and scavenger receptor
Marco (B), Il1b (IL-1β, C), Il6 (IL-6, D), Mmp9 (E) all
of which are involved in inﬂammatory activation of
microglia. HX600 failed to alter the expression of C3
(F). Data presented as mean ± SEM, 1-way ANOVA
with Bonferroni posthoc test, n= 3–5, **p < 0.01
and ***p < 0.001.
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signiﬁcant 59% increase in inﬁltrating CD45Hi CD11bLow lymphocytes
Fig. 7B) and 53% increase in Ly6CHi CD45Low cells, which can be either
inﬁltrating monocytes or activated microglia Fig. 7C), compared to
sham operated mice. The levels of these inﬁltrating cell populations
were signiﬁcantly reduced in HX600 treated mice. Of note is that
ischemia induced a small, yet signiﬁcant loss of resident CD45Low F4/
80Hi Ly6CLow microglia, which was prevented by HX600 treatment
Fig. 7D).
3.6. HX600 treatment normalizes metabolic proﬁle in the peri-ischemic area
To evaluate stroke induced changes in the levels of metabolites as
well as those altered by the HX600 treatment, we carried out high-
throughput metabolic proﬁling analysis of the peri-ischemic and the
contralateral brain samples (1 dpi) of the HX600 or vehicle treated
stroked mice. Results of the analysis are shown in Figs. 8 and 9, and in
Supplementary Table 1.
Supplementary data associated with this article can be found, in the
online version, at https://doi.org/10.1016/j.bbi.2018.07.021.
Ischemia was associated with alterations in levels of multiple me-
tabolites compared to the contralateral hemisphere (Supplementary
Table 2). These included signiﬁcantly increased levels of several acyl-
carnitines (e.g. hexanoylcarnitine, acylcarnitine 18:0, acylcarnitine
18:2, and acylcarnitine 22:6), lysophosphatidylcholines (lysoPCs, e.g.
lysoPC 14:0, lysoPC 16:0, lysoPC 18:1, lysoPC 20:4 and lysoPC 22:6), as
well as amino acid metabolites (e.g. 5-hydroxyindoleacetic acid [5-
HIAA], and trigonelline). On the contrary, ischemia resulted in decrease
in several metabolites including amino acids and amino acid metabo-
lites (e.g. N-acetylaspartate [NAA], and glutamate), nucleosides and
their metabolites (e.g. adenosine, adenosine 5′-monophosphate [AMP],
guanosine, and guanosine 5′-monophosphate [GMP]), and metabolites
associated with antioxidant responses (e.g. glutathione and oxidized
glutathione). Of note is that when using glutamate exposures to mimic
stroke induced excitotoxic insult, it reﬂects the situation immediately
after stroke, whereas these reduced metabolite levels are observed after
longer time period when the neurons are already dead.
HX600 treatment normalized the ischemia induced alterations in
several metabolites (Fig. 9). Speciﬁcally, HX600 prevented the
ischemia-induced increase in the levels of acylcarnitine 10:0, acylcar-
nitine 16:0, acylcarnitine 16:3, acylcarnitine 18:0, acylcarnitine 18:1,
acylcarnitine 18:2, and acylcarnitine 18:3 (Fig. 9). Similarly, ischemia
induced increase in the levels of lysoPC 14:0, lysoPC 16:0, lysoPC 16:1,
lysoPC 18:0, lysoPC 18:1 and ADP-ribose in HX600 treated animals
were normalized to the level of the unaﬀected brain hemisphere and
that of vehicle treated controls.
Fig. 3. HX600 protects neurons from LPS induced death. Primary microglia or BV2 cells were added on top of primary cortical neurons, and the co-cultures were pre-
exposed to HX600 or vehicle for 6 h. After that the cultures received either vehicle or LPS/IFNγ treatment, while HX600 concentration was maintained at 1 µM.
HX600 signiﬁcantly prevented neuronal death. Representative images of the neurons stained with MAP-2 (A) and quantitative analysis (B) from a primary microglia –
neuron co-culture. Transfection of BV2 cells with Nurr1 siRNA resulted in 40% knock-down of Nurr1 (C). When the neurons were co-cultured with Nurr1 siRNA
transfected BV2 cells, the protective eﬀect of HX600 against the inﬂammation induced neuronal death was abolished (D). Mock transfection of BV2 cells with control
siRNA did not prevent the protection (E). Data presented as mean ± SD, 1-way ANOVA followed by Bonferroni posthoc test (B, D and E) and unpaired two-tailed T-
test (C), n=3–12 wells in each group, each assay repeated three times. *p < 0.05 **p < 0.01 ***p < 0.001.
Fig. 4. HX600 reduces ischemic damage and im-
proves motor functions in vivo. Lesion size was
measured with MRI imaging 48 h after the ischemic
insult. Among the HX600 treated mice it was 21%
smaller when compared to mice treated with ve-
hicle. Quantitative analysis (A) and representative
MRI-images from mice receiving vehicle (B) and
HX600 treatment (C). In Latency to move -test
ischemia caused clear deterioration of motor func-
tion 1 day after the insult (D). HX600 treatment
brought the performance back to the level of sham
operated mice. Data presented as mean ± SEM,
Unpaired two-tailed T-test (A) and 1-way ANOVA followed by Bonferroni posthoc test (D), A: n=8 in both groups, B: n= 8 in vehicle treated stroke group, 7 in
HX600 treated stroke group and 12 in sham group. *p < 0.05.
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4. Discussion
The nuclear receptor NR4A2/Nurr1 is well known for its ability to
confer protection in models of PD. NR4A activation also supports
memory enhancement (Hawk et al., 2012) and mediates neuronal
survival in neuropathological conditions (Volakakis et al., 2010). Yet,
there is very little evidence about the role of NR4A in cerebral stroke.
Merino-Zamorano C et al found that Nurr1 induction in endothelial
cells after delayed administration of r-tPA contributes to endothelial
dysfunction, suggesting that Nurr1 activation may contribute to side-
eﬀects of r-tPA treatment (Merino-Zamorano et al., 2015). However, no
studies have assessed whether NR4A agonism confers neuroprotection
in ischemic stroke.
HX600 has been shown to have pan-agonistic activity on RXRs, and
additionally it is able to synergize with retinoic acid receptor (RAR)
(Umemiya et al., 1997; Umemiya et al., 1997). In addition, HX600 can
activate nuclear receptor NR4A1/Nurr77 (Morita et al., 2005; Ishizawa
et al., 2012). Our in vitro data Fig. 3 indicate that the beneﬁcial eﬀects
of HX600 may be mediated through Nurr1 receptor activation. How-
ever, we cannot rule out the possibility of HX600 activating also other
RXR heterodimers and RARs in vivo contributing to the beneﬁcial eﬀects
of the treatment.
Here we report for the ﬁrst time that HX600, an activator for Nurr1/
Nurr77, has anti-inﬂammatory eﬀects both in vitro and in vivo. Although
it failed to directly prevent neuronal death against glutamate induced
toxicity, it prevents inﬂammation induced neuronal death and facil-
itates neuronal survival post stroke. At the brain metabolite level,
HX600 treatment normalized the levels of metabolites related to in-
ﬂammatory and oxidative functions. Considering the known ability of
Nurr1 to inhibit inﬂammatory reactions (Saijo et al., 2009; Ishizawa
et al., 2012; Lallier et al., 2016; McMorrow and Murphy, 2011) we
propose that targeting Nurr1 provides a novel therapeutic target for
ischemic stroke. However, further studies are needed to evaluate
whether HX600 can provide protection with delayed administration
and whether the protection persist over longer time periods.
HX600 reduced the expression levels of several pro-inﬂammatory
mediators, including NOS2 (iNOS), Marco, Il1b (IL-1β), Il6 (IL-6) and
Mmp9 in primary microglia exposed to LPS. All of the analyzed in-
ﬂammatory mediators are induced in conditions of ischemic stroke
(Milne et al., 2005; Niwa et al., 2001; Lambertsen et al., 2012). Marco is
a scavenger receptor expressed in microglia and macrophages, and its
upregulation has been closely linked to microglial activation and pha-
gocytosis (Granucci et al., 2003) and Mmp9 is a proteinase with the
ability to degrade extracellular matrix proteins and in conditions of
stroke, cause blood brain barrier (BBB) damage and aggravate further
proinﬂammatory responses (Cauwe et al., 2007; Sandoval and Witt,
2008). iNOS is released by glial cells during inﬂammation leading to
excess amount of nitric oxide which in turn results in tissue damage
(Abdel-Salam et al., 2017). iNOS has been shown to be mainly re-
sponsible for the inﬂammation induced neuron death in the microglia-
neuron co-culture model (Gresa-Arribas et al., 2012) and thus it is not
surprising that HX600 potently prevented the inﬂammation induced
loss of MAP-2 immunoreactivity in this model.
Despite of Nurr1 receptor being abundantly expressed in cortical
neurons (Yasuyoshi et al., 2003), HX600 failed to show any beneﬁt in
our in vitro -model of excitotoxicity. This may be due to the fact that in
pure cortical neuron cultures the neurons are lacking the support they
get from the surrounding cells in vivo when such a crisis occurs. Glu-
tamate induced neuronal death is caused by loss of intracellular calcium
homeostasis (Vaarmann et al., 2013). Cytosolic calcium concentration
Fig. 5. HX600 reduces Iba-1, phospho-p38 and TREM2 immunoreactivities in the ischemic brain. Quantitative analysis of the Iba-1, phospho-p38 and TREM2
immunoreactivities (A–C), and typical representative images of group receiving vehicle (D–F) or HX600 treatment (G–I) at time point 1 day after the insult.
Immunoreactivities of Iba-1 and phospho-p38 were analyzed from the peri-ischemic area, and TREM2 at the lesion site. Scale bar 100 µm. Data presented as
mean ± SD. Unpaired two-tailed t-test, n= 8 in each group. *p < 0.05 ***p < 0.001.
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is rising shortly after glutamate exposure, goes down again and after
that a delayed, more sustained elevation follows, causing a severe dis-
ruption to the mitochondrial membrane potential and subsequent
neuronal death (Stout and Reynolds, 1999; Abramov and Duchen,
2010). It may be that mere neuronal Nurr1 induction by itself is not
enough to save the neurons from a severe insult like this, situation
being diﬀerent in vivo where HX600 aﬀects also the surrounding non-
neuronal cells, including microglia and inﬁltrating immune cell sup-
pressing their activation and subsequently alleviating the stroke in-
duced secondary neuronal damage. Whether HX600 also suppresses the
expression of chemotactic factors by brain resident cells is possible, yet
beyond the scope of this study.
The anti-inﬂammatory capacity of HX600 was further outlined by
the fact that HX600 treated animals showed reduced levels of Iba-1 and
phospho-p38, a serine/threonine protein kinase with important role in
microglial activation and inﬂammatory cytokine production
(Bachstetter et al., 2011). The anti-inﬂammatory eﬀect of HX600 driven
Nurr1 activation is likely to be mediated through the previously de-
scribed capacity of Nurr1 to diminish NFkB activation (Saijo et al.,
2009; De Miranda et al., 2015). Indeed, NFkB has been shown to drive
the expression of iNOS (Marks-Konczalik et al., 1998; Ozawa et al.,
2004). In addition, p38 has been shown to be able to activate NFkB
(Madrid et al., 2001) and concomitantly, inhibition of p38 and NFkB
signaling is beneﬁcial in ischemic stroke (Koistinaho et al., 2002; Nurmi
et al., 2004; Zhao et al., 2017; Rolova et al., 2016).
The anti-inﬂammatory capacity of HX600 also impacted microglia
morphology. Microglial cells in the healthy brain are in ramiﬁed shape
with long processes constantly inspecting the environment
(Nimmerjahn et al., 2005). When microglia get activated, they adopt
more amoeboid morphology characterized by shorter processes which
are also fewer in number, and larger soma compared to a ramiﬁed cell
(Perry et al., 2010). These changes aﬀect the area and perimeter of the
cell; the rounder the shape gets, the shorter is the perimeter and the
larger the area/perimeter -ratio. The microglia morphology analysis
showed that Iba-1 positive cells in the peri-ischemic area of HX600
treated mice have larger perimeter and smaller area/perimeter -ratio
when compared to vehicle treated mice, being one more attestation
towards the anti-inﬂammatory capacity of HX600.
As inﬁltrating leucocytes contribute to ischemia induced neuroin-
ﬂammation, we carried out ﬂow cytometry analysis to investigate how
HX600 alters immune cell inﬁltration, and chose the time point of the
peak in macrophage inﬁltration (Huuskonen et al., 2017). Our data
show that HX600 reduced the proportion of inﬁltrating CD45Hi
CD11bLow lymphocytes and Ly6CHi CD45Low inﬁltrating monocytes (or
activated microglia), thus contributing to the reduced pro-in-
ﬂammatory milieu in the post-ischemic brain. Moreover, HX600 pre-
vented the loss of endogenous microglia suggesting protection of mi-
croglia against ischemic insult.
Surprisingly the extent of TREM2 immunoreactivity was reduced in
the ischemic lesion of HX600 treated animals. TREM2 is most promi-
nently expressed in the brain by microglia (Colonna, 2003), although
the level of expression may vary between diﬀerent brain areas (Schmid
et al., 2002). TREM2 has been suggested to facilitate recovery from
brain injuries by promoting phagocytosis and dampening inﬂammation
(Hsieh et al., 2009; Kawabori et al., 2015). However, recent studies
indicate that downregulation of TREM2 is unexpectedly mitigating in-
ﬂammation and microglial activation, and is protective against neu-
ronal damage (Kobayashi et al., 2016; Leyns et al., 2017; Saber et al.,
2016; Sieber et al., 2013). One possible mechanism for this seemingly
contradictory result might be found from a study conducted by Charles
et al (Charles et al., 2008), where bacterial infection was seen to induce
TREM2 expression which in turn contributed to reactive oxygen species
(ROS) production and aggravation of inﬂammation (Charles et al.,
2008). Since ROS production is heavily involved in inﬂammation fol-
lowing stroke (Sanderson et al., 2013), it is possible that down-
regulation of TREM2 expression is aﬀecting inﬂammation reaction via
ROS production similarly as in inﬂammation induced by bacteria. Of
note is that it may take several days until TREM2 expression increases
after ischemia; in both permanent (Kawabori et al., 2015) and transient
(Sieber et al., 2013) models the peak in TREM2 levels was observed at
7 days after the insult. Since in this study TREM2 immunoreactivity was
quantiﬁed at the lesion area in early time point, the stained cells were
most likely inﬁltrating macrophages or leukocytes and thus the reduc-
tion in TREM2 may reﬂect the overall reduced number of inﬁltrating
cells.
Ischemic stroke is associated with alterations in several brain me-
tabolites, many of which are associated with inﬂammatory functions.
Only a few papers have described metabolic proﬁling of brain of rodent
stroke models at various time points post stroke (Huang et al., 2018;
Feng et al., 2017). Our analysis of the peri-ischemic area and the un-
aﬀected contralateral side revealed decreased levels of amino acids and
amino acid metabolites (e.g. N-acetyl aspartate [NAA], and glutamate)
reﬂective of the alterations in the excitatory processes in cerebral
ischemia. In addition, stroke reduced the levels of nucleosides and their
metabolites (e.g. adenosine, adenosine 5′-monophosphate [AMP],
guanosine, and guanosine 5′-monophosphate [GMP]), and metabolites
associated with antioxidant responses (e.g. glutathione and oxidized
glutathione). These data are also in line with that of previously pub-
lished in a transient ischemia model in mice (Mulder et al., 2016) and in
rats (Miura et al., 2010). NAA is considered as a metabolic marker for
mitochondria and related to neuronal viability (Céline et al., 2004) and
our data are in line with a previous study showing decreased brain
levels of NAA and glutamate both at very acute (Yan et al., 2015) as
well as at 7 days post stroke in rats (Huang et al., 2018).
Of the stroke induced increases of brain metabolites, HX600
Fig. 6. HX600 treatment alters morphology of Iba-1 expressing microglia.
Microglia in resting state (A) are characterized by long processes and relatively
small soma. When the cells get activated (B), their soma gets larger and pro-
cesses are shortening, which leads to decreased cell perimeter and increased
Area/Perimeter – ratio. Quantitative analysis of cell perimeter (C) and area/
perimeter – ratio (D) of Iba-1 positive cells, and representative images of the
algorithm used to determine the morphology of microglia in mice treated with
vehicle (E) or HX600 (F). Microglia are pseudocolored to aid identiﬁcation.
Data presented as mean ± SD. Unpaired two-tailed t-test, n= 8 in each group.
*p < 0.05.
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treatment normalized the levels of acylcarnitines, lysoPCs and adeno-
sine diphosphate (ADP) ribose in the ischemic side of the brain com-
pared to vehicle treated controls. Importantly, these molecules can be
associated with ischemia induced disruption of mitochondrial function
and activation of inﬂammatory reactions (Jin et al., 2010; Sanderson
et al., 2013).
Acylcarnitines are formed from fatty acids by carnitine palmitoyl-
transferase 1 (CPT1) and serve as an intermediate form, which can be
transported by carnitine acylcarnitine translocase (CACT, SLC25A20)
into the mitochondria for β-oxidation of fatty acids. Increased levels of
acylcarnitines in the peri-ischemic side of the brain may therefore be
linked to disrupted mitochondrial function, which HX600 treatment
seems to normalize. Importantly, acylcarnitines have been shown to
activate proinﬂammatory signaling pathways and subsequent induction
in various proinﬂammatory mediators, including IL-1β, IL-6
(Rutkowsky et al., 2014), and activation of NFκB pathway (Adams
et al., 2009) in macrophages further suggesting the ability of HX600 to
diminish inﬂammation.
LysoPCs are made when one fatty acid group is removed from
phosphatidylcholines most often by lipoprotein-associated phospholi-
pase A2 (Lp-PLA2). Under normal conditions, lysophospholipase and
LysoPC-acyltransferase then quickly metabolize LysoPCs. However,
increased LysoPC and Lp-PLA2 levels have been reported in response to
ischemic stroke in animals and humans (Adibhatla et al., 2004; Koizumi
et al., 2010; Cucchiara et al., 2009; Tsai et al., 2012); and elevated
levels of these molecules have been associated with increased NFkB
activation (Masamune et al., 2001; Jiang et al., 2014) LysoPCs increase
the recruitment of macrophages and microglia when released from
apoptotic cells and adjacent neurons and astrocytes (Lauber et al.,
2003; Inose et al., 2015). Thus, increased levels of LysoPCs in the is-
chemic brain may be associated with increased recruitment of macro-
phages and microglia, which has been considered to contribute to the
ischemic brain injury (Jin et al., 2010) and therefore, HX600 may be
able to reduce this recruitment by normalizing the levels of LysoPCs.
ADP-ribose is a building block of polyADP-ribose (PAR) chains,
which are formed by enzyme polyADP-ribose polymerase (PARP).
PARP is activated by single-strand DNA damage (in combination with
other DNA-repairing enzymes). Pharmacological inhibition of this
Fig. 7. HX600 reduces proportions of lymphocytes and inﬁltrating macrophages at 3dpi. Gating strategy showing the cell populations analyzed (A). Quantiﬁed ratios
of CD45Hi CD11bLow inﬁltrating lymphocytes (B) and Ly6CHi CD45Low inﬁltrating monocytes or activated microglia (C) and CD45Low F4/80Hi Ly6CLow resident
microglia (D). Data presented as mean ± SD. 1-way ANOVA followed by Bonferroni posthoc, n= 6 in stroke groups, n=4 in sham group. *p < 0.05.
Fig. 8. Overview of the metabolite proﬁling results. 1220 molecular features
were detected from the brain samples collected at 1 dpi. When control group
brain samples from the ischemic side (PI) were compared to the contralateral
side (CL), we observed 414 signiﬁcantly altered molecular features (x-axis
showing reversed log p -values from this comparison). From these, 47 molecular
features were signiﬁcantly diﬀerent between the ischemic side brain samples
from HX600 treated animals and controls (top right quadrant). These molecular
features in the top right quadrant were the ones where we observed an eﬀect of
both the ischemia and HX600 treatment. Molecular features in the bottom right
quadrant were aﬀected by the ischemia but not by the HX600 treatment, and
molecular features in the top left quadrant were aﬀected by the HX600 treat-
ment but not by ischemia. CL= contralateral side brain sample, PI= ischemic
side brain sample, HX600=HX600 treated group, VEH=vehicle treated
group, p= p-value from t-test. n= 6 mice in each group.
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Fig. 9. HX600 normalizes levels of acylcarnitines and LysoPCs in the ischemic side of the brain. HX600 treatment normalized the stroke-induced levels of acyl-
carnitines (A-G), adenosine diphosphate ribose (ADP-ribose, H), and lysophosphatidylcholines (lysoPCs, I-M) in the peri-ischemic area compared to vehicle treated
controls. HX600 failed to prevent the stroke-induced alterations in the levels of N-acetylaspartate (NAA; N), adenosine 5′-monophosphate (AMP; O) and 5-hydro-
xyindoleacetic acid (5-HIAA; P). Data presented as mean ± 95% conﬁdence interval. CL= contralateral side brain sample, PI= ischemic side brain sample,
VEH=vehicle treated mice, HX600=HX600 treated mice. n=6 mice in each group. *p < 0.05, **p < 0.01, ***p < 0.001.
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process has been suggested as a treatment option for ischemic brain
damage (Strosznajder et al., 2010). Furthermore, ADP-ribose can acti-
vate transient receptor potential cation channel M2 (TRPM2) (Fonfria
et al., 2004). The physiological role of TRPM2 is still unclear. The
TRPM2 gene is highly expressed in the brain, and it has been associated
with activation NLRP3 inﬂammasome (Zhong et al., 2013). Increased
ADP-ribose levels in the ischemic side brain samples in the vehicle
treated control samples may therefore be associated with increased
single-strand DNA damage and inﬂammation processes, and by redu-
cing ADP-ribose levels, HX600 treatment may reduce these processes.
Taken together, our data show a prominent anti-inﬂammatory role
for HX600 that is driven by Nurr1 activation. Treatment strategies
targeting Nurr1 may be beneﬁcial for treatment of conditions involving
neuroinﬂammation including ischemic stroke.
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